Urdaneta M, Prata A, Struchiner C J, Tosta C E, Tauil P, Boulos M
Escola Nacional de Saude Publica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Am J Trop Med Hyg. 1998 Mar;58(3):378-85. doi: 10.4269/ajtmh.1998.58.378.
This paper reports the efficacy results of the randomized, placebo-controlled, field trial of SPf66 malaria vaccine in Costa Marques, Rondonia, Brazil. This region is characterized by the seasonal distribution of Plasmodium falciparum and P. vivax infections, and the recent occupation by migrants from nonendemic areas. A total of 800 individuals of both sexes, ranging in age from seven to 60 years, were included in the study. Of the initial cohort, 572 participants completed the vaccination schedule. Clinical and parasitologic evaluations were obtained by active and passive searches on a periodic basis. The overall protective efficacy against P. falciparum infections was -1.6% (-32.9% to 22.4%), and 14.1% (-17.0% to 36.9%) for the first episode. The overall protective efficacy for P. vivax infections was -19.7% (-44.8% to 1.03%), and -10.8% (-41.1% to 12.8%) for the first episode. No statistical evidence of an overall significant protective effect of SPf66 malaria vaccine against P. falciparum and P. vivax malaria was obtained in this trial.
本文报告了SPf66疟疾疫苗在巴西朗多尼亚州科斯塔马克斯进行的随机、安慰剂对照现场试验的疗效结果。该地区的特点是恶性疟原虫和间日疟原虫感染呈季节性分布,且近期有来自非流行地区的移民迁入。共有800名年龄在7至60岁之间的男女纳入该研究。在最初的队列中,572名参与者完成了疫苗接种计划。通过定期主动和被动搜索进行临床和寄生虫学评估。针对恶性疟原虫感染的总体保护效力为-1.6%(-32.9%至22.4%),首次发作时为14.1%(-17.0%至36.9%)。针对间日疟原虫感染的总体保护效力为-19.7%(-44.8%至1.03%),首次发作时为-10.8%(-41.1%至12.8%)。在该试验中,未获得SPf66疟疾疫苗对恶性疟原虫和间日疟原虫疟疾具有总体显著保护作用的统计学证据。